Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma
DOI:
https://doi.org/10.3889/oamjms.2018.062Keywords:
Meningioma, Hemangiopericytoma, Schwannoma, Claudin - 1, SSTR2AAbstract
BACKGROUND: The distinction between meningioma, schwannoma and solitary fibrous tumour/ hemangiopericytoma can be challenging in some cases. This study evaluates the expression of Somatostatin receptor 2A (SSTR2A) and Claudin-1 in these different tumours.
MATERIAL AND METHODS: Thirty-five cases of meningioma, 10 cases of intracranial schwannoma and 10 cases of hemangiopericytoma were assessed. The immunohistochemical expression of SSTR2A and Claudin-1 was evaluated and scored according to the percentage of immunostained tumour cells (0: 1+, 2+ and 3). The intensity of staining was classified as weak, moderate and strong.
RESULTS: Positivity for SSTR2A and Claudin-1 was encountered in 89% and 49% of meningiomas respectively. None of the schwannomas or hemangiopericytomas was positive for any of both markers. All grade I and II meningiomas were positive for SSTR2A, and only 20% of grade III showed positive staining (p < 0.05). Claudin-1 positivity was detected in 50%, 43% and 60% of grade I, II and III meningioma respectively, with significantly higher intensity in grade III (p < 0.05).
CONCLUSION: SSTR2A is highly sensitive and specific for meningioma. Claudin-1 is highly specific for meningioma, with low sensitivity. The adjunctive use of both markers can be very helpful in the diagnosis of meningioma and its distinction from schwannoma and hemangiopericytoma.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y et al. Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007– 2011. Neuro-oncology. 2014; 16 (suppl-4):iv1-63. https://doi.org/10.1093/neuonc/nou223 PMid:25304271 PMCid:PMC4193675
Cushing H. The meningiomas (dural endotheliomas): their source and favored seats of origin (Cavendish Lecture). Brain. 1922; 45: 282-316. https://doi.org/10.1093/brain/45.2.282
Perry A, Louis DN, Scheithauer BW, Budka H and Von Deimling A. Meningioma. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumors of the central nervous system; pp 164-172. Lyon: IARC, 2007.
Perry A, Louis DN, Scheithauer BW, Budka H and Von Deimling A. Meningioma. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumors of the central nervous system; Lyon: IARC, 2016: 223-224. PMid:27512595 PMCid:PMC4967785
Perry A. Meningiomas. In Perry A and Brat DJ (eds). Practical surgical neuropathology; pp 185-217, Chruchill Livingstone, Philadelphia, 2010. https://doi.org/10.1016/B978-0-443-06982-6.00010-9
Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. The American journal of surgical pathology. 1997; 21(12):1455-65. https://doi.org/10.1097/00000478-199712000-00008 PMid:9414189
Rajaram V, Brat DJ, Perry A. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Human pathology. 2004;35(11):1413-8. https://doi.org/10.1016/j.humpath.2004.07.017 PMid:15668900
Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003; 20(3):255-64. https://doi.org/10.1385/ENDO:20:3:255
Cervia D, Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacology & therapeutics. 2007; 116(2):322-41. https://doi.org/10.1016/j.pharmthera.2007.06.010 PMid:17719647
Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. Journal of neuro-oncology. 2004; 66(1-2):155-66. https://doi.org/10.1023/B:NEON.0000013498.19981.55 PMid:15015781
Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008; 13(1):822-40. https://doi.org/10.2741/2722
Dutour A, Kumar U, Panetta R, Ouafik L, Fina F et al.. Expression of somatostatin receptor subtypes in human brain tumors. International journal of cancer. 1998; 76(5):620-7. https://doi.org/10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S
Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clinical Cancer Research. 2000; 6(5):1865-74. PMid:10815909
Hahn HP, Bundock EA, Hornick JL. Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics. American journal of clinical pathology. 2006; 125(2):203-8. https://doi.org/10.1309/G659FVVBMG7U4RPQ PMid:16393681
Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer research. 2005; 65(21):9603-6. https://doi.org/10.1158/0008-5472.CAN-05-2782 PMid:16266975
Stebbing J, Filipović A, Giamas G. Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene. 2013; 32(41):4871-2. https://doi.org/10.1038/onc.2012.591 PMid:23318416
Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L et al. Increased 68Ga- DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. Journal of Nuclear Medicine. 2015; 56(3):347-53. https://doi.org/10.2967/jnumed.114.149120 PMid:25635133
Bacchi CE, Kandalaft PL, Hwang HC, Goldstein LC, Lopes LL et al. Somatostatin Receptor 2A: A Novel Immunohistochemical Marker of Meningioma. In Laboratory Investigation. 2013 Feb 1; (Vol. 93, pp. 414A-414A). 75 Varick St, 9th Flr, New York, NY 10013-1917 USA: Nature Publishing Group.
Agaimy A, Buslei R, Coras R, Rubin BP, Mentzel T. Comparative study of soft tissue perineurioma and meningioma using a fiveâ€marker immunohistochemical panel. Histopathology. 2014; 65(1):60-70. https://doi.org/10.1111/his.12366 PMid:24393170
Menke JR, Gown AM, Thomas S, Perry A, Tihan T. Reliability of Somatostatin Receptor 2a as a Marker of Meningioma: An Immunohistochemical Study. Laboratory Investigation. 2014; 94:439a-439a).
Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncology reports. 2008; 20(3):485-92. PMid:18695896
Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J et al. Expression of c- Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clinical neuropathology. 2007; 27(5):334-45.
Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clinical cancer research. 1996; 2(10):1757-65. PMid:9816127
Qiu CZ, Wang C, Huang ZX, Zhu SZ, Wu YY et al. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World Journal of Gastroenterology: WJG. 2006; 12(13):2011. https://doi.org/10.3748/wjg.v12.i13.2011 PMid:16610049 PMCid:PMC4087677
Soini Y, Rauramaa T, Alafuzoff I, Sandell PJ, Kärjä V. Claudins 1, 11 and twist in meningiomas. Histopathology. 2010; 56(6):821-4. https://doi.org/10.1111/j.1365-2559.2010.03538.x PMid:20546350
Singh AB, Sharma A, Dhawan P. Claudin family of proteins and cancer: an overview. Journal of oncology. 2010; 2010.
Kantarjian HM, Wolff RA. The MD Anderson manual of medical oncology. McGraw Hill Educational, 2016:848.
Graillon T, Defilles C, Mohamed A, Lisbonis C, Germanetti AL et al. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. Journal of neuro-oncology. 2015; 124(1):33-43. https://doi.org/10.1007/s11060-015-1812-3 PMid:26015296
Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma Salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69(10):969-73. https://doi.org/10.1212/01.wnl.0000271382.62776.b7 PMid:17785665
Bural GG, Lieberman F, Mountz JM. Use of 111In-pentetreotide scan in a subject with treatment refractory atypical meningioma. Clinical nuclear medicine. 2014; 39(4):342-5. https://doi.org/10.1097/RLU.0000000000000326 PMid:24445268
Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015; 84(3):280-6. https://doi.org/10.1212/WNL.0000000000001153 PMid:25527270 PMCid:PMC4335993
Simó M, Argyriou AA, Macià M, Plans G, Majós C et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer chemotherapy and pharmacology. 2014; 73(5):919-23. https://doi.org/10.1007/s00280-014-2422-z PMid:24619496
Hashimoto Y, Tada M, Iida M, Nagase S, Hata T et al. Generation and characterization of a human–mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model. Biochemical and biophysical research communications. 2016; 477(1):91-5. https://doi.org/10.1016/j.bbrc.2016.06.025 PMid:27286708
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
